Publications by authors named "Alkes A Khotko"
Background: Plaque psoriasis affects ~ 1% of the pediatric population, negatively impacting quality of life. The efficacy and safety of secukinumab in pediatric patients with moderate to severe or severe chronic plaque psoriasis have been established in two pivotal phase 3 trials (open-label, NCT03668613; double-blind, NCT02471144).
Objectives: The aims were to report the pooled safety of secukinumab up to 52 weeks from two studies in subgroups of pediatric patients stratified by age and bodyweight, and to present, alongside the pediatric data, the pooled safety data from four pivotal adult secukinumab trials.
Article Synopsis
- The study aimed to compare the effectiveness, safety, and pharmacokinetics of BCD-057 with the well-known drug adalimumab (iADA) for treating moderate to severe plaque psoriasis.
- A total of 346 patients participated, with 60% of BCD-057 users achieving significant improvement at week 16, showing both drugs are similarly effective over time.
- Both treatments exhibited comparable safety profiles, and switching from iADA to BCD-057 did not impact the patients' immune response, confirming their similarity.